These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35837802)

  • 1. Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kapoor M; Carr A; Foiani M; Heslegrave A; Zetterberg H; Malaspina A; Compton L; Hutton E; Rossor A; Reilly MM; Lunn MP
    Eur J Neurol; 2022 Nov; 29(11):3347-3357. PubMed ID: 35837802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neurofilament light chain does not detect self-reported treatment-related fluctuations in chronic inflammatory demyelinating polyneuropathy.
    Poser PL; Sajid GS; Beyer L; Hieke A; Schumacher A; Horstkemper L; Karl AS; Grüter T; Sgodzai M; Pitarokoili K; Gerwert K; Gold R; Fisse AL; Gisevius B; Motte J
    Eur J Neurol; 2024 Jan; 31(1):e16023. PubMed ID: 37539836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
    Adrichem ME; Eftimov F; van Schaik IN
    J Peripher Nerv Syst; 2016 Sep; 21(3):121-7. PubMed ID: 27241239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
    Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
    Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; van Doorn PA; Bengrine T; van Rijs W; Baas F; Nagelkerke SQ; Kuijpers TW; Fokkink WR; Bunschoten C; Broers MC; Willemsen SP; Jacobs BC; Huizinga R
    Eur J Neurol; 2021 May; 28(5):1677-1683. PubMed ID: 33460483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
    J Peripher Nerv Syst; 2017 Dec; 22(4):425-432. PubMed ID: 29092099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
    Silsby M; Yiannikas C; Ng K; Kiernan MC; Fung VSC; Vucic S
    Muscle Nerve; 2022 Jan; 65(1):43-50. PubMed ID: 34383335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.
    van Lieverloo GGA; Wieske L; Verhamme C; Vrancken AFJ; van Doorn PA; Michalak Z; Barro C; van Schaik IN; Kuhle J; Eftimov F
    J Peripher Nerv Syst; 2019 Jun; 24(2):187-194. PubMed ID: 30973667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
    Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H
    J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
    Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
    Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
    Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
    Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
    J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).
    Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
    J Peripher Nerv Syst; 2018 Mar; 23(1):5-10. PubMed ID: 29119642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Adrichem ME; Lucke IM; Vrancken AFJE; Goedee HS; Wieske L; Dijkgraaf MGW; Voermans NC; Notermans NC; Faber CG; Visser LH; Kuitwaard K; van Doorn PA; Merkies ISJ; de Haan RJ; van Schaik IN; Eftimov F
    Brain; 2022 Jun; 145(5):1641-1652. PubMed ID: 35139161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
    Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
    Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of intravenous immunoglobulin in CIDP.
    Vucic S; Black K; Baldassari LE; Tick Chong PS; Dawson KT; Cros D
    Clin Neurophysiol; 2007 Sep; 118(9):1980-4. PubMed ID: 17604689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
    Hansen PN; Mohammed AA; Markvardsen LK; Andersen H; Tankisi H; Sindrup SH; Krøigård T
    J Peripher Nerv Syst; 2023 Sep; 28(3):425-435. PubMed ID: 37212187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
    Ritter C; Bobylev I; Lehmann HC
    J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.